A5082851780- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Viral gastroenteritis research and epidemiology
- Liver Disease and Transplantation
- Hepatitis Viruses Studies and Epidemiology
- COVID-19 Clinical Research Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Salmonella and Campylobacter epidemiology
- Clostridium difficile and Clostridium perfringens research
- Animal Virus Infections Studies
- Systemic Lupus Erythematosus Research
- Microscopic Colitis
- Infectious Diseases and Tuberculosis
- Herpesvirus Infections and Treatments
- SARS-CoV-2 and COVID-19 Research
- COVID-19 and healthcare impacts
- Global Health Workforce Issues
- Rabies epidemiology and control
- Pesticide Exposure and Toxicity
- Cassava research and cyanide
- Peripheral Nerve Disorders
- Food Security and Health in Diverse Populations
- T-cell and Retrovirus Studies
- Long-Term Effects of COVID-19
Spitalul Clinic Dr. Victor Babes
2015-2025
Carol Davila University of Medicine and Pharmacy
2016-2025
Institutul National Victor Babes
2025
Université Paris Cité
2024
Centre de Recherche des Cordeliers
2024
Université Claude Bernard Lyon 1
2024
Assistance Publique – Hôpitaux de Paris
2024
Hôpital Cochin
2024
Centre de Recherche sur l'Inflammation
2024
Sorbonne Université
2024
In a phase 3 trial, bulevirtide monotherapy led to virologic response in patients with chronic hepatitis D. Pegylated interferon (peginterferon) alfa-2a is recommended by guidelines as an off-label treatment for this disease. The role of combination therapy and peginterferon alfa-2a, particularly regard finite treatment, unclear.
Abstract Background Chronic Hepatitis Delta (CHD) is the most severe form of viral hepatitis. Bulevirtide (BLV) a first-in-class entry inhibitor approved in EU for treatment compensated CHD. In MYR204, Phase 2b study evaluating finite with BLV or without pegylated interferon alfa-2a (Peg-IFNa), combination 10mg resulted higher undetectable HDV RNA rates 24 weeks (W) post end (EOT) compared either monotherapy regimen. Here, we present predictors at 48W (FU-48) post-EOT.Table 1.Comparison Key...
Background/Objectives: Although a “forgotten” disease in developed countries, typhoid fever remains significant global health problem, especially regions with inadequate sanitation and overcrowding. Despite medical advances, this systemic bacterial infection, caused by Salmonella Typhi, continues to affect millions worldwide. Accurate diagnosis timely treatment are crucial prevent severe complications mortality. Even though antibiotic therapy is effective, the emergence of drug-resistant...
Abstract Background and Aims Chronic hepatitis delta represents a major global health burden. Clinical features of D virus (HDV) infection vary largely between different regions worldwide. Treatment approaches are dependent on the approval status distinct drugs financial resources. Methods The Hepatitis Delta International Network (HDIN) registry involves researchers from all continents (Wranke, Liver 2018). We here report long‐term follow‐up data 648 patients recruited by 14 centres in 11...
Ultrasound elastography is perhaps the most important breakthrough in evolution of ultrasonography last 15 years. Since transient was introduced, many other methods have been developed and became more widely available. The value ultrasound staging a chronic liver disease has established by numerous studies. There studies that shown using it possible to predict presence complications cirrhosis: portal hypertension, esophageal varices (and even their risk bleeding) hepatocellular carcinoma. It...
Pegylated interferon alpha 2a continues to be used for the treatment of chronic hepatitis D. The reported on-treatment virologic response varies between 17 and 47%, with relapses in more than 50% these patients. No stopping rules have been defined, duration is not clearly established, but it should 48 96 weeks. In total, 76 patients compensated liver disease treated peg-interferon according Romanian National protocol D were retrospectively included. was up weeks, following rules: less a 2...
Streptococcus alactolyticus is a non-motile Gram-positive, catalase-negative cocci, part of group D Streptococci. In the literature, S. documented as causative agent infective endocarditis, demonstrated by blood cultures in only four other cases, representing an extremely rare circumstance. Here, we describe case endocarditis due to young patient known with bicuspid aortic valve and associated sigmoid precancerous polyp. The was also have hypertension type II diabetes. Symptoms at debut...
<h3>Background</h3> Bulevirtide (BLV) is a first-in-class entry inhibitor approved in the EU for treatment of chronic HDV infection (CHD). This Phase 2 study (MYR204) evaluated safety and efficacy BLV with or without peginterferon alfa-2a (PegIFN) patients CHD compensated liver disease. <h3>Methods</h3> 174 were randomized stratified based on absence presence cirrhosis to receive (A) PegIFN 48 weeks (w); (B) 2mg + (C) 10mg 48w, both followed by 48w monotherapy 10mg, respectively; (D) 96w....
<h3>Background</h3> Bulevirtide (BLV) is approved in Europe for the treatment of chronic hepatitis D (CHD). Optimal BLV monotherapy duration CHD unknown). This analysis evaluated pts without VR after 24W. <h3>Methods</h3> Results from who completed 96W Phase 3 (MYR301) and 2 (MYR204) studies were included. NR PR defined as HDV RNA declines <1 log10 IU/mL ≥1 but <2 IU/mL, respectively. Rates biochemical response (alanine aminotransferase [ALT] within normal limits [WNL]) compared....
, an anaerobic bacillus ubiquitous in nature, is the leading cause of hospital-acquired diarrhoea and one main causes mortality by nosocomial infections. We aimed to identify predictors risk dying characteristics a three-year cohort patients hospitalised our clinic that eventually had unfavourable outcome.
Introduction: The emergence of carbapenem-resistant pathogenic bacteria is a growing global public health concern. Carbapenem-resistant uropathogenic strains Klebsiella pneumoniae can cause uncomplicated or complicated urinary tract infections, leading to high risk treatment failure and the spread resistance determinants. objectives this 24-month study were identify prognostic characteristics patients who infected with (CRKpn) create tool estimate probability CRKpn infection before having...